There are currently 9 active clinical trials seeking participants for Psoriatic Arthritis research studies. The states with the highest number of trials for Psoriatic Arthritis participants are .
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis
NCT06624228
Recruiting
The purpose of the study is to compare the efficacy of bimekizumab versus risankizumab after 16 weeks of treatment in study participants with active psoriatic arthritis (PsA).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: Pa0016 50662, Gilbert, Arizona +143 locations
Conditions: Psoriatic Arthritis
Register for Updates
Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis
NCT06865105
Recruiting
Psoriatic arthritis (PsA) is a type of arthritis that happens when the body's immune system attacks healthy cells and tissues causing joint pain, stiffness, and swelling. Symptoms can get worse and go away for periods of time. This study will evaluate the efficacy and safety of targeted therapies through a series of substudies, for the treatment of active psoriatic arthritis and to assess the changes in disease symptoms. The therapies being assessed in this sub-study are risankizumab and lutiki... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Newport Huntington Medical Group /ID# 272764, Huntington Beach, California +21 locations
Conditions: Psoriatic Arthritis
Register for Updates
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
NCT06671496
Recruiting
Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO). The main aim of the study is to know how well zasocitinib (TAK-279) works in participants with active PsA based on their previous experience with specific treatments. The participants will be treated with either zasocitinib, or placebo. Participants will be in the study for up to 60 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: Arizona Arthritis & Rheumatology Research, PLLC | Phoenix, AZ, Mesa, Arizona +122 locations
Conditions: Psoriatic Arthritis
Register for Updates
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
NCT03816345
Recruiting
This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +51 locations
Conditions: Autoimmune Disease, Crohn Disease, Dermatomyositis, Inflammatory Bowel Disease, Multiple Sclerosis, Rheumatoid Arthritis, Sjogren Syndrome, Systemic Lupus Erythematosus, Systemic Scleroderma, Ulcerative Colitis, Hematopoietic and Lymphoid Cell Neoplasm, Psoriasis, Psoriatic Arthritis, Malignant Solid Neoplasm
Register for Updates
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
NCT06888193
Recruiting
Primary purpose of the study is to assess the concentration of bimekizumab in mature human breast milk.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: Up0122 202, Calgary, Not set
Conditions: Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Axial Spondyloarthritis, Hidradenitis Suppurativa
Register for Updates
Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis
NCT04991116
Recruiting
An open label phase 3 study
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: Sunpharma site no 50, Dothan, Alabama +96 locations
Conditions: Psoriatic Arthritis
Register for Updates
Modifying PEST for Psoriatic Arthritis Screening
NCT06382051
Recruiting
The purpose of this study is to assess the impact of adding two questions and pictures to the validated PEST on the potential diagnosis of PsA in participants with moderate-to-severe plaque PsO in Canada.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/10/2025
Locations: Novartis Investigative Site, Hamilton, Ontario +1 locations
Conditions: Plaque Psoriasis, Psoriatic Arthritis
Register for Updates
A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis
NCT06454188
Recruiting
A Randomized, Placebo-controlled, Multicenter, Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients with Active Psoriatic Arthritis (UP-SPOUT)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2025
Locations: Oregon Health and Science University, Portland, Oregon +3 locations
Conditions: Psoriatic Arthritis, Spondyloarthritis, Axial
Register for Updates
Sex and Gender-based Analysis of the Effectiveness of Advanced Therapies in Psoriatic Arthritis
NCT05954364
Recruiting
Sex and gender are important factors that influence treatment response in PsA. The goal of this multi-centre observational study is to understand how sex and gender influence response to advanced therapies in psoriatic arthritis (PsA). The investigators hope to discover biological and socio-cultural mechanisms that explain the differences in treatment response between men and women with PsA. The study investigators plan to recruit patients from approximately 30 sites across the world. Men and w... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/20/2023
Locations: Women's College Hospital, Toronto, Ontario
Conditions: Psoriatic Arthritis
Register for Updates